查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1772235

美国微量残存疾病检测市场规模、份额、趋势分析报告（按技术、癌症类型、最终用途、细分市场预测），2025-2033

U.S. Minimal Residual Disease Testing Market Size, Share & Trends Analysis Report By Technology (Flow Cytometry, PCR, NGS), By Cancer Type (Hematological Malignancy, Solid Tumors), By End Use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

市场规模与趋势：

预计 2024 年美国微量残存疾病检测市场价值将达到 8.7366 亿美元，2025 年至 2033 年期间的复合年增长率为 9.38%。

这是在中国癌症负担日益加重、医疗体系越来越重视精准医疗的背景下发生的。

根据最近的预测，到2024年，美国将有约89,190人被诊断出患有淋巴瘤，包括何杰金氏病和非何杰金氏病淋巴瘤。预计死亡人数为21,050人，其中非何杰金氏淋巴瘤在男性中更为常见，且死亡率更高。这项令人担忧的统计数据凸显了对高灵敏度早期检测工具的迫切需求，例如MRD检测。 MRD检测使医生能够在患者治疗后，即使病情看似缓解，也能检测到残留的癌细胞痕迹。这项技术在识别高復发风险患者、指导进一步治疗和改善长期疗效方面发挥关键作用。

向基于价值的护理和个人化治疗方案的转变，正在将MRD检测从一种可选的研究工具提升为主流临床必需品。随着癌症治疗变得更加精准和适应性更强，对MRD检测等精准疾病监测工具的需求也日益增长。这一趋势在骨髓恶性肿瘤尤其明显，MRD状态在临床试验和现实世界治疗方案中越来越多地被用作替代终点。

近年来，次世代定序(NGS) 和流式细胞技术快速发展，提高了 MRD 检测的准确性、可重复性和临床实用性。 FDA核准的检测，例如 Adaptive Biotechnologies 公司用于检测多发性骨髓瘤、急性淋巴细胞白血病 (ALL) 和慢性淋巴性白血病(CLL) 的 clonoSEQ，为检测灵敏度和采用率树立了新的标竿。同样，Natera 公司 Signatera 是一种基于肿瘤资讯性 ctDNA 的 MRD 检测，在固体癌管理（包括结直肠癌、乳癌和膀胱癌）中越来越受欢迎。这些检测可用于长期疾病追踪、个人化治疗决策和早期发现復发。

目录

第一章调查方法与范围

第二章美国微量残存疾病检测市场：执行摘要

  • 市场概述
  • 技术与服务概览
  • 癌症类型和最终用途简介
  • 竞争格局简介

第三章美国微量残存疾病检测市场变数、趋势与范围

  • 市场区隔和范围
  • 市场展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
  • 市场驱动因素分析
    • 造血系统恶性肿瘤发生率和盛行率不断上升
    • 诊断工具的技术进步
    • 与个人化医疗的整合
  • 市场限制因素分析
    • 先进的 MRD 技术高成本，使用受限
  • 美国微量残存疾病检测市场分析工具
    • 产业分析-波特五力分析
    • PESTLE分析

第四章美国的微量残存疾病检测：技术评估与趋势分析

  • 2024 年及 2033 年技术市场占有率
  • 细分仪表板
  • 美国微量残存疾病检测市场技术展望
  • 2021 年至 2033 年市场规模、预测与趋势分析
    • 流式细胞技术
    • 聚合酵素链锁反应（PCR）
    • 次世代定序（NGS）
    • 其他的

第五章美国的微量残存疾病检测：癌症类型估计和趋势分析

  • 2024年及2033年癌症类型市场占有率
  • 细分仪表板
  • 美国微量残存疾病检测市场：癌症类型展望
  • 2021 年至 2033 年市场规模、预测与趋势分析
    • 造血系统恶性肿瘤
    • 固态肿瘤

第六章微量残存疾病检测：最终用途估计与趋势分析

  • 2024年及2033年最终用途市场占有率
  • 细分仪表板
  • 美国微量残存疾病检测市场前景（依最终用途）
  • 2021 年至 2033 年市场规模、预测与趋势分析
    • 医院和专科诊所
    • 诊断实验室
    • 学术研究所
    • 其他的

第七章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要经销商和通路合作伙伴名单
    • Key Customers
    • Key Company Market Share Analysis, 2024
    • Twist Bioscience
    • Thermo Fisher Scientific, Inc
    • Illumina, Inc.
    • QIAGEN
    • Adaptive Biotechnologies
    • Natera, Inc.
    • Guardant Health
    • Foresight Diagnostics, Inc.
    • NeoGenomics, Inc.
    • Hoffmann-La Roche Ltd.
    • SOPHiA GENETICS
Product Code: GVR-4-68040-651-7

Market Size & Trends:

The U.S. minimal residual disease testing market was estimated at USD 873.66 million in 2024 and is projected to grow at a CAGR of 9.38% from 2025 and 2033, driven by the country's rising cancer burden and the healthcare system's growing emphasis on precision medicine.

According to recent projections, about 89,190 people in the U.S. will be diagnosed with lymphoma in 2024, encompassing both Hodgkin and non-Hodgkin types. An estimated 21,050 deaths are anticipated, with non-Hodgkin lymphoma being both more common and deadlier, especially in men. These alarming statistics underscore the urgent demand for highly sensitive, early detection tools like MRD testing. MRD testing enables physicians to detect trace levels of cancer cells that persist after treatment, even when patients appear to be in remission. This technology plays a vital role in identifying patients at high risk of relapses, guiding further therapy, and improving long-term outcomes.

The shift toward value-based care and personalized treatment plans has elevated MRD testing from an optional research tool to a mainstream clinical necessity. As cancer therapies become more targeted and adaptive, the demand for precise disease monitoring tools like MRD testing continues to grow. This trend is especially pronounced in hematologic malignancies, where MRD status is increasingly being used as a surrogate endpoint in clinical trials and real-world treatment protocols.

Recent years have witnessed rapid advancements in next-generation sequencing (NGS) and flow cytometry, making MRD detection more accurate, reproducible, and clinically actionable. FDA-cleared tests such as Adaptive Biotechnologies' clonoSEQ for multiple myeloma, acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL) have set new benchmarks for test sensitivity and adoption. Similarly, Natera's Signatera, a tumor-informed ctDNA-based MRD test, is gaining traction in solid tumor management, including colorectal, breast, and bladder cancers. These assays allow for longitudinal disease tracking, personalized treatment decisions, and the early detection of recurrence-often months before symptoms or imaging changes appear.

U.S. Minimal Residual Disease Testing Market Report Segmentation

This report forecasts revenue growth at regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. minimal residual disease testing market report based on the technology, cancer type, and end use:

  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Flow Cytometry
  • Polymerase Chain Reaction (PCR)
  • Next Generation Sequencing (NGS)
    • Amplicon-based NGS
    • Hybridization Capture-based NGS
    • Others
  • Others
  • Cancer Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Hematological Malignancy
    • Leukemia
    • Lymphoma
  • Solid Tumors
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals and Specialty Clinics
  • Diagnostic Laboratories
  • Academic and Research Institutes
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Technology Segment
      • 1.1.1.2. Cancer Type Segment
      • 1.1.1.3. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Primary Sources
  • 1.11. List of Abbreviations

Chapter 2. U.S. Minimal Residual Disease Testing Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Technology and Services Snapshots
  • 2.3. Cancer Type and End Use Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. U.S. Minimal Residual Disease Testing Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Rising incidence and prevalence of hematological malignancies
    • 3.4.2. Technological advancements in diagnostic tools
    • 3.4.3. Integration with personalized medicines
  • 3.5. Market Restraint Analysis
    • 3.5.1. High cost and limited accessibility of advanced MRD technologies
  • 3.6. U.S. Minimal Residual Disease Testing Market Analysis Tools
    • 3.6.1. Industry Analysis - Porter's
      • 3.6.1.1. Supplier Power
      • 3.6.1.2. Buyer Power
      • 3.6.1.3. Substitution Threat
      • 3.6.1.4. Threat of New Entrants
      • 3.6.1.5. Competitive Rivalry
    • 3.6.2. PESTLE Analysis
      • 3.6.2.1. Political Landscape
      • 3.6.2.2. Technological Landscape
      • 3.6.2.3. Economic Landscape

Chapter 4. U.S. Minimal Residual Disease Testing: Products, Estimates & Trend Analysis

  • 4.1. Product Market Share, 2024 & 2033
  • 4.2. Segment Dashboard
  • 4.3. U.S. Minimal Residual Disease Testing Market, By Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 To 2033 For The Following
    • 4.4.1. Flow Cytometry
      • 4.4.1.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
    • 4.4.2. Polymerase Chain Reaction (PCR)
      • 4.4.2.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
    • 4.4.3. Next Generation Sequencing (NGS)
      • 4.4.3.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
      • 4.4.3.2. Amplicon-based NGS
        • 4.4.3.2.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
      • 4.4.3.3. Hybridization Capture-based NGS
        • 4.4.3.3.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
      • 4.4.3.4. Others
        • 4.4.3.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)

Chapter 5. U.S. Minimal Residual Disease Testing: Cancer Type Estimates & Trend Analysis

  • 5.1. Cancer Type Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. U.S. Minimal Residual Disease Testing Market, By Cancer Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 To 2033 For The Following
    • 5.4.1. Hematological Malignancy
      • 5.4.1.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 5.4.1.2. Leukemia
        • 5.4.1.2.1. Market Estimates and Forecasts 2021 To 2033 (USD Million)
      • 5.4.1.3. Lymphoma
        • 5.4.1.3.1. Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 5.4.2. Solid Tumors
      • 5.4.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Minimal Residual Disease Testing: End Use Estimates & Trend Analysis

  • 6.1. End Use Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global U.S. Minimal Residual Disease Testing Market, By End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 To 2033 For The Following
    • 6.4.1. Hospitals and Specialty Clinics
      • 6.4.1.1. Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 6.4.2. Diagnostic Laboratories
      • 6.4.2.1. Market Estimates and Forecasts 2021 To 2033 (USD Million)
    • 6.4.3. Academic and Research Institutes
    • 6.4.4. Others
      • 6.4.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company /Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of Key Distributors and Channel Partners
    • 7.3.2. Key Customers
    • 7.3.3. Key Company Market Share Analysis, 2024
    • 7.3.4. Twist Bioscience
      • 7.3.4.1. Overview
      • 7.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.4.3. Product Benchmarking
      • 7.3.4.4. Strategic Initiatives
    • 7.3.5. Thermo Fisher Scientific, Inc
      • 7.3.5.1. Overview
      • 7.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.5.3. Product Benchmarking
      • 7.3.5.4. Strategic Initiatives
    • 7.3.6. Illumina, Inc.
      • 7.3.6.1. Overview
      • 7.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.6.3. Product Benchmarking
      • 7.3.6.4. Strategic Initiatives
    • 7.3.7. QIAGEN
      • 7.3.7.1. Overview
      • 7.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.7.3. Product Benchmarking
      • 7.3.7.4. Strategic Initiatives
    • 7.3.8. Adaptive Biotechnologies
      • 7.3.8.1. Overview
      • 7.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.8.3. Product Benchmarking
      • 7.3.8.4. Strategic Initiatives
    • 7.3.9. Natera, Inc.
      • 7.3.9.1. Overview
      • 7.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.9.3. Product Benchmarking
      • 7.3.9.4. Strategic Initiatives
    • 7.3.10. Guardant Health
      • 7.3.10.1. Overview
      • 7.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.10.3. Product Benchmarking
      • 7.3.10.4. Strategic Initiatives
    • 7.3.11. Foresight Diagnostics, Inc.
      • 7.3.11.1. Overview
      • 7.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.11.3. Product Benchmarking
      • 7.3.11.4. Strategic Initiatives
    • 7.3.12. NeoGenomics, Inc.
      • 7.3.12.1. Overview
      • 7.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.12.3. Product Benchmarking
      • 7.3.12.4. Strategic Initiatives
    • 7.3.13. Hoffmann-La Roche Ltd.
      • 7.3.13.1. Overview
      • 7.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.13.3. Product Benchmarking
      • 7.3.13.4. Strategic Initiatives
    • 7.3.14. SOPHiA GENETICS
      • 7.3.14.1. Overview
      • 7.3.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.3.14.3. Product Benchmarking
      • 7.3.14.4. Strategic Initiatives

List of Tables

  • Table 1. List of key distributors and channel partners
  • Table 2. List of key emerging companies'/technology disruptors/innovators
  • Table 3. U.S. Minimal Residual Disease Testing Market, By Product, 2021 - 2033 (USD Million)
  • Table 4. U.S. Minimal Residual Disease Testing Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 5. U.S. Minimal Residual Disease Testing Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 U.S. Minimal Residual Disease Testing Market Segmentation
  • Fig. 8 Market Snapshot, 2024
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
  • Fig. 14 Porter's Five Forces Analysis
  • Fig. 15 Market Penetration Vs Growth Prospect Mapping, 2024
  • Fig. 16 U.S. Minimal Residual Disease Testing Market: Product Movement Analysis
  • Fig. 17 U.S. Minimal Residual Disease Testing Market: Product Outlook and Key Takeaways
  • Fig. 18 Flow Cytometry
  • Fig. 19 Polymerase Chain Reaction (PCR)
  • Fig. 20 Next Generation Sequencing (NGS)
  • Fig. 21 Others Market Estimates and Forecast, 2021 - 2033
  • Fig. 22 Amplicon-based NGS Market Estimates and Forecast, 2021 - 2033
  • Fig. 23 Hybridization Capture-based NGS Market Estimates and Forecast, 2021 - 2033
  • Fig. 24 Other Estimates and Forecast, 2021 - 2033
  • Fig. 25 U.S. Minimal Residual Disease Testing Market: Cancer Type Movement Analysis
  • Fig. 26 U.S. Minimal Residual Disease Testing Market: Cancer Type Outlook and Key Takeaways
  • Fig. 27 Hematological Malignancy Market Estimates and Forecasts, 2021 - 2033
  • Fig. 28 Solid Tumors Market Estimates and Forecasts, 2021 - 2033
  • Fig. 29 Blood & Blood-based Products Market Estimates and Forecasts,2021 - 2033
  • Fig. 30 Leukemia Market Estimates and Forecasts,2021 - 2033
  • Fig. 31 Lymphoma Market Estimates and Forecasts,2021 - 2033
  • Fig. 32 U.S. Minimal Residual Disease Testing Market: End Use Movement Analysis
  • Fig. 33 U.S. Minimal Residual Disease Testing Market: End Use Outlook and Key Takeaways
  • Fig. 34 Hospitals and Specialty Clinics Market Estimates and Forecasts, 2021 - 2033
  • Fig. 35 Diagnostic Laboratories Market Estimates and Forecasts, 2021 - 2033
  • Fig. 36 Academic and Research Institutes Market Estimates and Forecasts, 2021 - 2033
  • Fig. 37 Others Market Estimates and Forecasts, 2021 - 2033